aimmune therapeutics appoints eric bjerkholt as chief financial officerhomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets open in  hrs  minssp futures dow futuresundefined nasdaq futures97 aimmune therapeutics appoints eric bjerkholt as chief financial officerbusiness wireapril  reblogsharetweetsharebrisbane califbusiness wireaimmune therapeutics inc aimt today announced the appointment of eric bjerkholt as chief financial officermr bjerkholt joins aimmune from sunesis pharmaceuticals inc where over  years with the company his role as cfo expanded to oversee multiple aspects of governance corporate relations and other functions in addition to taking sunesis through its initial public offering in  he raised more than  million for the company in other financings prior to sunesis mr bjerkholt was cfo at intrabiotics pharmaceuticals inc and lifespring nutrition inc he began his healthcare career at jp morgan  co as an investment banker in new york and then launched the company’s western us healthcare practice mr bjerkholt holds a cand oecon master’s degree in economics from the university of oslo and an mba from harvard business school he has served on the boards of directors of several publicly traded companies and is currently a member of the board of directors and chair of the audit committee for corium international inc“i am delighted to further strengthen our executive team with the addition of eric bjerkholt” said aimmune ceo stephen dilly mbbs phd “eric’s deep understanding and direct experience of multiple facets of corporate finance and other related activities will be key assets in the years ahead”“this is a very exciting time to join aimmune” said mr bjerkholt “the lead product ar is very promising peanut allergy is a significant unmet need and aimmune is in a very strong financial position the company plans to report pivotal phase  data around the end of  file a bla and maa in  and make first commercial launches in 9 although there is much to be done aimmune has a highly experienced management team in place and is wellequipped to meet the challenges ahead i am enthusiastic to get started at the end of april”about aimmune therapeuticsaimmune therapeutics inc is a clinicalstage biopharmaceutical company developing treatments for lifethreatening food allergies the company’s characterized oral desensitization immunotherapy codit™ approach is intended to achieve meaningful levels of protection by desensitizing patients with defined precise amounts of key allergens aimmune’s first investigational biologic product using codit™ ar for the treatment of peanut allergy has received the fda’s breakthrough therapy designation for the desensitization of peanutallergic patients  years of age and is currently being evaluated in phase  clinical trials for more information please see wwwaimmunecomforwardlooking statementsstatements contained in this press release regarding matters that are not historical facts are “forwardlooking statements” within the meaning of the private securities litigation reform act of 99 because such statements are subject to risks and uncertainties actual results may differ materially from those expressed or implied by such forwardlooking statements such statements include but are not limited to statements regarding aimmune’s expectations for its phase  palisade trial of ar including its expected size and timing of topline data aimmune’s expectations regarding the potential benefits of ar aimmune’s expectations regarding the sufficiency of its capital resources aimmune’s expectations for the ramses and artemis studies including the timing of the trials aimmune’s expectations on regulatory submissions for marketing approval of ar in the united states and europe including the timing of these submissions and aimmune’s expectations regarding potential applications of the codit™ approach to treating lifethreatening food allergies risks and uncertainties that contribute to the uncertain nature of the forwardlooking statements include the expectation that aimmune will need additional funds to finance its operations the company’s ability to initiate andor complete clinical trials the unpredictability of the regulatory process the possibility that aimmune’s clinical trials will not be successful aimmune’s dependence on the success of ar the company’s reliance on third parties for the manufacture of the company’s product candidates possible regulatory developments in the united states and foreign countries and the company’s ability to attract and retain senior management personnel these and other risks and uncertainties are described more fully in aimmunes most recent filings with the securities and exchange commission including its annual report on form k for the year ended december   all forwardlooking statements contained in this press release speak only as of the date on which they were made aimmune undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were maderead morethis press release concerns a product that is under clinical investigation and that has not yet been approved for marketing by the us food and drug administration fda or the european medicines agency ema it is currently limited to investigational use and no representation is made as to its safety or effectiveness for the purposes for which it is being investigatedview source version on businesswirecom httpwwwbusinesswirecomnewshomeenreblogsharetweetsharerecently viewedyour list is emptywhat to read nexta big fall in markets is coming as traders put record cash to workbusiness insiderhow  lifethreatening events changed how aetnas ceo views health careyahoo financejeb bush calls out republicans who criticized obama over russia but have been silent on the trumprussia probebusiness insideraetna ceo bertolini how tech plays into the future of healthcareyahoo finance videoaetnas ceo mark bertolini on the future of the health care systemyahoo financeamazon is going underwater seriouslyfortune years after korean war north still digging up bombsassociated presssupreme court ruling leads to offensive trademark requestsreutersaetna ceo bertolini why he pays his employees to sleepyahoo finance videowhy it might be ‘dangerous’ for ibm to turn itself around professoryahoo financewhy sparkling water sales could spike by  in yahoo financehow to save money when youre youngyahoo financebillionaire investor chris sacca told an amazing story about how obsessed kobe bryant is with being a successful investor in the startup worldbusiness insideraetna ceo bertolini how his own accident and son’s cancer changed his journeyyahoo finance videocall of the week nows the time to buy chipotleyahoo financescaramucci quotes anonymous source on russian hacking then admits trump was the sourcebusiness insiderscaramuccis message to huckabee sanders keep the same hair and makeup teamn w he is a pig just like his bossjoin the conversation   aimmune therapeutics appoints eric bjerkholt as chief financial officer  marketwatch bulletin investor alert new york markets open in market snapshot analyst ratings press release april    am edt aimmune therapeutics appoints eric bjerkholt as chief financial officer — new cfo is an established leader and healthcare industry veteran — brisbane calif apr   business wire  aimmune therapeutics inc quoteszigman9composite aimt   today announced the appointment of eric bjerkholt as chief financial officer mr bjerkholt joins aimmune from sunesis pharmaceuticals inc where over  years with the company his role as cfo expanded to oversee multiple aspects of governance corporate relations and other functions in addition to taking sunesis through its initial public offering in  he raised more than  million for the company in other financings prior to sunesis mr bjerkholt was cfo at intrabiotics pharmaceuticals inc and lifespring nutrition inc he began his healthcare career at jp morgan  co as an investment banker in new york and then launched the company’s western us healthcare practice mr bjerkholt holds a cand oecon master’s degree in economics from the university of oslo and an mba from harvard business school he has served on the boards of directors of several publicly traded companies and is currently a member of the board of directors and chair of the audit committee for corium international inc “i am delighted to further strengthen our executive team with the addition of eric bjerkholt” said aimmune ceo stephen dilly mbbs phd “eric’s deep understanding and direct experience of multiple facets of corporate finance and other related activities will be key assets in the years ahead” “this is a very exciting time to join aimmune” said mr bjerkholt “the lead product ar is very promising peanut allergy is a significant unmet need and aimmune is in a very strong financial position the company plans to report pivotal phase  data around the end of  file a bla and maa in  and make first commercial launches in 9 although there is much to be done aimmune has a highly experienced management team in place and is wellequipped to meet the challenges ahead i am enthusiastic to get started at the end of april” about aimmune therapeutics aimmune therapeutics inc is a clinicalstage biopharmaceutical company developing treatments for lifethreatening food allergies the company’s characterized oral desensitization immunotherapy codit™ approach is intended to achieve meaningful levels of protection by desensitizing patients with defined precise amounts of key allergens aimmune’s first investigational biologic product using codit™ ar for the treatment of peanut allergy has received the fda’s breakthrough therapy designation for the desensitization of peanutallergic patients  years of age and is currently being evaluated in phase  clinical trials for more information please see wwwaimmunecom  forwardlooking statements statements contained in this press release regarding matters that are not historical facts are “forwardlooking statements” within the meaning of the private securities litigation reform act of 99 because such statements are subject to risks and uncertainties actual results may differ materially from those expressed or implied by such forwardlooking statements such statements include but are not limited to statements regarding aimmune’s expectations for its phase  palisade trial of ar including its expected size and timing of topline data aimmune’s expectations regarding the potential benefits of ar aimmune’s expectations regarding the sufficiency of its capital resources aimmune’s expectations for the ramses and artemis studies including the timing of the trials aimmune’s expectations on regulatory submissions for marketing approval of ar in the united states and europe including the timing of these submissions and aimmune’s expectations regarding potential applications of the codit™ approach to treating lifethreatening food allergies risks and uncertainties that contribute to the uncertain nature of the forwardlooking statements include the expectation that aimmune will need additional funds to finance its operations the company’s ability to initiate andor complete clinical trials the unpredictability of the regulatory process the possibility that aimmune’s clinical trials will not be successful aimmune’s dependence on the success of ar the company’s reliance on third parties for the manufacture of the company’s product candidates possible regulatory developments in the united states and foreign countries and the company’s ability to attract and retain senior management personnel these and other risks and uncertainties are described more fully in aimmunes most recent filings with the securities and exchange commission including its annual report on form k for the year ended december   all forwardlooking statements contained in this press release speak only as of the date on which they were made aimmune undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made this press release concerns a product that is under clinical investigation and that has not yet been approved for marketing by the us food and drug administration fda or the european medicines agency ema it is currently limited to investigational use and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated view source version on businesswirecom httpwwwbusinesswirecomnewshomeen source aimmune therapeutics inc aimmune therapeutics inc investors laura hansen phd 9 lhansenaimmunecom media stephanie yao 79 syaoaimmunecom copyright business wire  quoteszigman9composite add to watchlist aimt aimmune therapeutics inc us  us nasdaq  7   volume  july   p pe rationa dividend yieldna market cap9 billion rev per employeena most popular  ‘game of thrones’ the four biggest takeaways from stormborn’  americans in this field have the highest rate of divorce by age   oj simpson made over  while in prison and won’t have to give any of it to the goldman family  the dark side of cruises  fix your iphones old battery find a broker partner center » featured stories seeing america again through new eyes how to dig yourself out of debt move over tesla karma unveils its hybrid sports car the salary you need to afford a home in these  cities why opec will never cut production again log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest ainvesting according to your values can also make you money ahere’s how wealthy americans keep the best for themselves awhat is a longterm time horizon for older investors agood news if you love coffee aeuropean stocks pull back as auto makers oil producers struggle awhat is a mancation and why are men taking them athe states where people spend the most on lotto tickets aparents are dropping  on plastic surgery while their kids are at sleepaway camp afundamentals how to raise  million with just  in your bank account a stupidly costly mistakes parents make when backtoschool shopping 9anobody puts  down on a house anymore ahow the opec committee’s meeting could make or break oil prices a stocks for betting on the rush away from cash a‘full transparency’ doesn’t mean what scaramucci apparently thinks it means aeurozone recovery may have peaked pmis suggest a‘game of thrones’ the four biggest takeaways from stormborn’ athe cracked benchmark why some investors want a new standard for bonds 9aa yearold ‘dunkirk’ survivor laments current state of the world ‘it never ends’ adollar edges higher recovering slightly from recent slide aoil prices move lower as opec meeting gets under way loading more headlines dow quoteszigman79realtime 7 7  nasdaq quoteszigman9realtime 77   sp  quoteszigman7realtime 7 9  kiosk 7 7 the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml 7   alerts congakioskalertshtml  7 9 virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml  7 7 location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml 7 99 99 lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  aimmune therapeutics appoints eric bjerkholt as chief financial officer  newswire aimmune therapeutics appoints eric bjerkholt as chief financial officer — new cfo is an established leader and healthcare industry veteran — press release  apr   april   press release  brisbane califaimmune therapeutics inc nasdaqaimt today announced the appointment of eric bjerkholt as chief financial officer i am delighted to further strengthen our executive team with the addition of eric bjerkholt mr bjerkholt joins aimmune from sunesis pharmaceuticals inc where over  years with the company his role as cfo expanded to oversee multiple aspects of governance corporate relations and other functions in addition to taking sunesis through its initial public offering in  he raised more than  million for the company in other financings prior to sunesis mr bjerkholt was cfo at intrabiotics pharmaceuticals inc and lifespring nutrition inc he began his healthcare career at jp morgan  co as an investment banker in new york and then launched the companys western us healthcare practice mr bjerkholt holds a cand oecon masters degree in economics from the university of oslo and an mba from harvard business school he has served on the boards of directors of several publicly traded companies and is currently a member of the board of directors and chair of the audit committee for corium international inc i am delighted to further strengthen our executive team with the addition of eric bjerkholt said aimmune ceo stephen dilly mbbs phd erics deep understanding and direct experience of multiple facets of corporate finance and other related activities will be key assets in the years ahead this is a very exciting time to join aimmune said mr bjerkholt the lead product ar is very promising peanut allergy is a significant unmet need and aimmune is in a very strong financial position the company plans to report pivotal phase  data around the end of  file a bla and maa in  and make first commercial launches in 9 although there is much to be done aimmune has a highly experienced management team in place and is wellequipped to meet the challenges ahead i am enthusiastic to get started at the end of april about aimmune therapeutics aimmune therapeutics inc is a clinicalstage biopharmaceutical company developing treatments for lifethreatening food allergies the companys characterized oral desensitization immunotherapy codit™ approach is intended to achieve meaningful levels of protection by desensitizing patients with defined precise amounts of key allergens aimmunes first investigational biologic product using codit™ ar for the treatment of peanut allergy has received the fdas breakthrough therapy designation for the desensitization of peanutallergic patients  years of age and is currently being evaluated in phase  clinical trials for more information please see wwwaimmunecom forwardlooking statements statements contained in this press release regarding matters that are not historical facts are forwardlooking statements within the meaning of the private securities litigation reform act of 99 because such statements are subject to risks and uncertainties actual results may differ materially from those expressed or implied by such forwardlooking statements such statements include but are not limited to statements regarding aimmunes expectations for its phase  palisade trial of ar including its expected size and timing of topline data aimmunes expectations regarding the potential benefits of ar aimmunes expectations regarding the sufficiency of its capital resources aimmunes expectations for the ramses and artemis studies including the timing of the trials aimmunes expectations on regulatory submissions for marketing approval of ar in the united states and europe including the timing of these submissions and aimmunes expectations regarding potential applications of the codit™ approach to treating lifethreatening food allergies risks and uncertainties that contribute to the uncertain nature of the forwardlooking statements include the expectation that aimmune will need additional funds to finance its operations the companys ability to initiate andor complete clinical trials the unpredictability of the regulatory process the possibility that aimmunes clinical trials will not be successful aimmunes dependence on the success of ar the companys reliance on third parties for the manufacture of the companys product candidates possible regulatory developments in the united states and foreign countries and the companys ability to attract and retain senior management personnel these and other risks and uncertainties are described more fully in aimmunes most recent filings with the securities and exchange commission including its annual report on form k for the year ended december   all forwardlooking statements contained in this press release speak only as of the date on which they were made aimmune undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made this press release concerns a product that is under clinical investigation and that has not yet been approved for marketing by the us food and drug administration fda or the european medicines agency ema it is currently limited to investigational use and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated source url httpbusinesswirecomnewshomeenaimmunetherapeuticsappointsericbjerkholtchieffinancial share on facebook share on twitter categories healthcare about aimmune therapeutics inc view website aimmune therapeutics develops treatments to protect children with food allergies peanut milk and egg from the consequences of accidental exposure more press releases aimmune therapeutics announces fourth quarter and full year  financial results — company began  with approximately  million in cash and investments sufficient to support current development plans through regulatory submissions — — conference call and webcast today at  am et — aimmune therapeutics inc  mar   aimmune therapeutics presents clinical data on phase  screening and phase  adherence for ar for peanut allergy at the  american academy of allergy asthma  immunology aaaai annual meeting — unique dataset of doubleblind placebocontrolled food challenges from phase  palisade north american screened population is largest ever collected on peanutallergic patients and provides valuable insights for future study — — 9 adherence to daily athome ar dosing in blinded phase  study — aimmune therapeutics inc  mar   aimmune therapeutics to present at the th annual jp morgan healthcare conference presentation on wednesday january   at  pm pacific time aimmune therapeutics inc  jan   newswire get notified about new releases sign up for email updates from newswire enter your email address notification frequency press releases instant daily never news instant daily never event instant daily never blog daily never facebook daily never twitter daily never subscribe aimmune therapeutics appoints eric bjerkholt as chief financial officer  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use 99 thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street aimmune therapeutics appoints eric bjerkholt as chief financial officer business wire apr    am edt aimmune therapeutics inc nasdaqaimt today announced the appointment of eric bjerkholt as chief financial officer mr bjerkholt joins aimmune from sunesis pharmaceuticals inc where over  years with the company his role as cfo expanded to oversee multiple aspects of governance corporate relations and other functions in addition to taking sunesis through its initial public offering in  he raised more than  million for the company in other financings prior to sunesis mr bjerkholt was cfo at intrabiotics pharmaceuticals inc and lifespring nutrition inc he began his healthcare career at jp morgan  co as an investment banker in new york and then launched the companys western us healthcare practice mr bjerkholt holds a cand oecon masters degree in economics from the university of oslo and an mba from harvard business school he has served on the boards of directors of several publicly traded companies and is currently a member of the board of directors and chair of the audit committee for corium international inc i am delighted to further strengthen our executive team with the addition of eric bjerkholt said aimmune ceo stephen dilly mbbs phd erics deep understanding and direct experience of multiple facets of corporate finance and other related activities will be key assets in the years ahead this is a very exciting time to join aimmune said mr bjerkholt the lead product ar is very promising peanut allergy is a significant unmet need and aimmune is in a very strong financial position the company plans to report pivotal phase  data around the end of  file a bla and maa in  and make first commercial launches in 9 although there is much to be done aimmune has a highly experienced management team in place and is wellequipped to meet the challenges ahead i am enthusiastic to get started at the end of april if you liked this article you might like  breakout stocks to buy for big gains these stocks look ready to break out and trade higher from current levels roberto pedone nov    am est  stocks ready for breakouts these stocks look ready to break out and trade higher from current levels roberto pedone sep    am edt trending trump just resurrected the ugly practice known as civil forfeiture for no reason walmart in focus amid horrific human trafficking incident in texas that causes nine deaths ftc seen as set to block rite aid deal billionaire mark cuban the rise of technology will cause a lot of unemployment as snap continues to stumble should it consider selling itself advertising partners 99 thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers aimmune appoints eric bjerkholt as chief financial officer employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       aimmune aimt appoints eric bjerkholt as chief financial officer tweet  7 am — new cfo is an established leader and healthcare industry veteran — brisbane califbusiness wireaimmune therapeutics inc nasdaqaimt today announced the appointment of eric bjerkholt as chief financial officer mr bjerkholt joins aimmune from sunesis pharmaceuticals inc where over  years with the company his role as cfo expanded to oversee multiple aspects of governance corporate relations and other functions in addition to taking sunesis through its initial public offering in  he raised more than  million for the company in other financings prior to sunesis mr bjerkholt was cfo at intrabiotics pharmaceuticals inc and lifespring nutrition inc he began his healthcare career at jp morgan  co as an investment banker in new york and then launched the company’s western us healthcare practice mr bjerkholt holds a cand oecon master’s degree in economics from the university of oslo and an mba from harvard business school he has served on the boards of directors of several publicly traded companies and is currently a member of the board of directors and chair of the audit committee for corium international inc “i am delighted to further strengthen our executive team with the addition of eric bjerkholt” said aimmune ceo stephen dilly mbbs phd “eric’s deep understanding and direct experience of multiple facets of corporate finance and other related activities will be key assets in the years ahead” “this is a very exciting time to join aimmune” said mr bjerkholt “the lead product ar is very promising peanut allergy is a significant unmet need and aimmune is in a very strong financial position the company plans to report pivotal phase  data around the end of  file a bla and maa in  and make first commercial launches in 9 although there is much to be done aimmune has a highly experienced management team in place and is wellequipped to meet the challenges ahead i am enthusiastic to get started at the end of april” about aimmune therapeutics aimmune therapeutics inc is a clinicalstage biopharmaceutical company developing treatments for lifethreatening food allergies the company’s characterized oral desensitization immunotherapy codit™ approach is intended to achieve meaningful levels of protection by desensitizing patients with defined precise amounts of key allergens aimmune’s first investigational biologic product using codit™ ar for the treatment of peanut allergy has received the fda’s breakthrough therapy designation for the desensitization of peanutallergic patients  years of age and is currently being evaluated in phase  clinical trials for more information please see wwwaimmunecom forwardlooking statements statements contained in this press release regarding matters that are not historical facts are “forwardlooking statements” within the meaning of the private securities litigation reform act of 99 because such statements are subject to risks and uncertainties actual results may differ materially from those expressed or implied by such forwardlooking statements such statements include but are not limited to statements regarding aimmune’s expectations for its phase  palisade trial of ar including its expected size and timing of topline data aimmune’s expectations regarding the potential benefits of ar aimmune’s expectations regarding the sufficiency of its capital resources aimmune’s expectations for the ramses and artemis studies including the timing of the trials aimmune’s expectations on regulatory submissions for marketing approval of ar in the united states and europe including the timing of these submissions and aimmune’s expectations regarding potential applications of the codit™ approach to treating lifethreatening food allergies risks and uncertainties that contribute to the uncertain nature of the forwardlooking statements include the expectation that aimmune will need additional funds to finance its operations the company’s ability to initiate andor complete clinical trials the unpredictability of the regulatory process the possibility that aimmune’s clinical trials will not be successful aimmune’s dependence on the success of ar the company’s reliance on third parties for the manufacture of the company’s product candidates possible regulatory developments in the united states and foreign countries and the company’s ability to attract and retain senior management personnel these and other risks and uncertainties are described more fully in aimmunes most recent filings with the securities and exchange commission including its annual report on form k for the year ended december   all forwardlooking statements contained in this press release speak only as of the date on which they were made aimmune undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made this press release concerns a product that is under clinical investigation and that has not yet been approved for marketing by the us food and drug administration fda or the european medicines agency ema it is currently limited to investigational use and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated aimmune therapeutics incinvestorslaura hansen phd 9lhansenaimmunecommediastephanie yao 79syaoaimmunecom read at biospacecom related news aimmune aimt presents clinical data on phase iii screening and phase  adherence for ar for peanut allergy at the  american academy of allergy asthma and immunology aaaai annual meeting good salary nice bonus—but why did biotech mogul david hung gamble on axovant axon aimmune aimt provides update on ongoing ar phase  program for peanut allergy based on fda feedback  things we learned about fda nominee scott gottlieb aimmune aimt announces fourth quarter and full year  financial results slam fda nominee gottlieb as being too cozy with big pharma to combat opioid epidemic aimmune aimt to release fourth quarter and full year  financial results on wednesday march   gottlieb as fda commissioner would be music to pharma’s ears bay areas aimmune aimt gets  million infusion from nestlé health science look out biotech google googs parent alphabet sets sights on poaching top talent from life sciences and healthcare please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • aimmune therapeutics   • biotechpharma  personnel                 corium announces appointment of eric h bjerkholt to board of directors nasdaqcori facebook google linkedin twitter email rss apr   previous release  next release pdf corium announces appointment of eric h bjerkholt to board of directors menlo park calif april   globe newswire  corium international inc nasdaqcori a commercialstage biopharmaceutical company focused on the development manufacture and commercialization of specialty transdermal products today announced the appointment of eric h bjerkholt to the companys board of directors and as chair of the boards audit committee   eric bjerkholt brings a wealth of strategic and management experience in finance business development corporate governance and operations in the biopharmaceutical sector  we look forward to his contributions as a member of our board as we advance our product programs and continue our growth as a public company said peter staple coriums president and chief executive officer   a senior executive with more than two decades of experience in the healthcare and life science sectors mr bjerkholt is executive vice president corporate development and finance and chief financial officer of sunesis pharmaceuticals inc having joined sunesis in  as senior vice president and chief financial officer  from  to  he was senior vice president and chief financial officer at intrabiotics pharmaceuticals inc a publiclyheld biopharmaceutical company  mr bjerkholt was a cofounder of lifespring nutrition inc a privatelyheld nutraceutical company and from 999 to  served at various times as its chief executive officer president and chief financial officer  he also served as vice president in the healthcare banking group at jp morgan  co from 99 to 9  mr bjerkholt is a member of the board of directors of stemcells inc a publiclyheld biotechnology company and ambrx inc a privatelyheld biopharmaceutical company  he holds a cand oecon degree in economics from the university of oslo and an mba from harvard business school corium also announced that john w kozarich phd will be retiring from the companys board and will continue as an advisor to the company  on behalf of coriums board i would like to recognize john kozarichs many contributions to the companys development during his long tenure of service on the board  johns extensive background in pharmaceutical industry research and development has been instrumental in helping us to position corium as a leader in transdermal product innovation said david l greenwood chairman of the board  about corium corium international inc is a commercialstage biopharmaceutical company focused on the development manufacture and commercialization of specialty pharmaceutical products that leverage the companys advanced transdermal and transmucosal delivery systems  corium has developed and is the sole commercial manufacturer of six prescription drug and consumer products with partners teva pharmaceuticals par pharmaceutical and procter  gamble  the company has two proprietary transdermal platforms corplex™ for small molecules and microcor® a biodegradable microstructure technology for small molecules and biologics including vaccines peptides and proteins  the companys latestage pipeline includes a contraceptive patch codeveloped with agile therapeutics that is currently in phase  trials and additional transdermal products that are being codeveloped with teva  corium has multiple proprietary programs in preclinical and clinical development for the treatment of osteoporosis and neurological disorders  for further information please visit wwwcoriumgroupcomforwardlooking statements this press release contains forwardlooking statements within the meaning of the us private securities litigation reform act of 99 including statements regarding our business strategy clinical trial plans and the advancement of our technologies and our proprietary and partnered products and product candidates  forwardlooking statements are based on managements current expectations and projections and are subject to risks and uncertainties which may cause coriums actual results to differ materially from the statements contained herein  further information on potential risk factors that could affect coriums business and its financial results are detailed in coriums quarterly report on form q for the quarter ended december   filed with the securities and exchange commission on february   and other reports as filed from time to time with the securities and exchange commission  undue reliance should not be placed on forwardlooking statements especially guidance on future financial performance which speaks only as of the date they are made  corium undertakes no obligation to update publicly any forwardlooking statements to reflect new information events or circumstances after the date they were made or to reflect the occurrence of unanticipated eventscontact investor and media contact karen l bergman bcc partners kbergmanbccpartnerscom 79 aimmune therapeutics appoints eric bjerkholt as chief financial officer  business wire aimmune therapeutics appoints eric bjerkholt as chief financial officer — new cfo is an established leader and healthcare industry veteran — april    am eastern daylight time brisbane califbusiness wireaimmune therapeutics inc nasdaqaimt today announced the appointment of eric bjerkholt as chief financial officer mr bjerkholt joins aimmune from sunesis pharmaceuticals inc where over  years with the company his role as cfo expanded to oversee multiple aspects of governance corporate relations and other functions in addition to taking sunesis through its initial public offering in  he raised more than  million for the company in other financings prior to sunesis mr bjerkholt was cfo at intrabiotics pharmaceuticals inc and lifespring nutrition inc he began his healthcare career at jp morgan  co as an investment banker in new york and then launched the company’s western us healthcare practice mr bjerkholt holds a cand oecon master’s degree in economics from the university of oslo and an mba from harvard business school he has served on the boards of directors of several publicly traded companies and is currently a member of the board of directors and chair of the audit committee for corium international inc “i am delighted to further strengthen our executive team with the addition of eric bjerkholt” said aimmune ceo stephen dilly mbbs phd “eric’s deep understanding and direct experience of multiple facets of corporate finance and other related activities will be key assets in the years ahead” “this is a very exciting time to join aimmune” said mr bjerkholt “the lead product ar is very promising peanut allergy is a significant unmet need and aimmune is in a very strong financial position the company plans to report pivotal phase  data around the end of  file a bla and maa in  and make first commercial launches in 9 although there is much to be done aimmune has a highly experienced management team in place and is wellequipped to meet the challenges ahead i am enthusiastic to get started at the end of april” about aimmune therapeutics aimmune therapeutics inc is a clinicalstage biopharmaceutical company developing treatments for lifethreatening food allergies the company’s characterized oral desensitization immunotherapy codit™ approach is intended to achieve meaningful levels of protection by desensitizing patients with defined precise amounts of key allergens aimmune’s first investigational biologic product using codit™ ar for the treatment of peanut allergy has received the fda’s breakthrough therapy designation for the desensitization of peanutallergic patients  years of age and is currently being evaluated in phase  clinical trials for more information please see wwwaimmunecom forwardlooking statements statements contained in this press release regarding matters that are not historical facts are “forwardlooking statements” within the meaning of the private securities litigation reform act of 99 because such statements are subject to risks and uncertainties actual results may differ materially from those expressed or implied by such forwardlooking statements such statements include but are not limited to statements regarding aimmune’s expectations for its phase  palisade trial of ar including its expected size and timing of topline data aimmune’s expectations regarding the potential benefits of ar aimmune’s expectations regarding the sufficiency of its capital resources aimmune’s expectations for the ramses and artemis studies including the timing of the trials aimmune’s expectations on regulatory submissions for marketing approval of ar in the united states and europe including the timing of these submissions and aimmune’s expectations regarding potential applications of the codit™ approach to treating lifethreatening food allergies risks and uncertainties that contribute to the uncertain nature of the forwardlooking statements include the expectation that aimmune will need additional funds to finance its operations the company’s ability to initiate andor complete clinical trials the unpredictability of the regulatory process the possibility that aimmune’s clinical trials will not be successful aimmune’s dependence on the success of ar the company’s reliance on third parties for the manufacture of the company’s product candidates possible regulatory developments in the united states and foreign countries and the company’s ability to attract and retain senior management personnel these and other risks and uncertainties are described more fully in aimmunes most recent filings with the securities and exchange commission including its annual report on form k for the year ended december   all forwardlooking statements contained in this press release speak only as of the date on which they were made aimmune undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made this press release concerns a product that is under clinical investigation and that has not yet been approved for marketing by the us food and drug administration fda or the european medicines agency ema it is currently limited to investigational use and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated contacts aimmune therapeutics incinvestorslaura hansen phd 9lhansenaimmunecommediastephanie yao 79syaoaimmunecom contacts aimmune therapeutics incinvestorslaura hansen phd 9lhansenaimmunecommediastephanie yao 79syaoaimmunecom search advanced news search advanced news search log in sign up eric h bjerkholt board dir stemcells inc a publisher of business information since 9        search business search executive   advanced search   sign in    hints profile of eric bjerkholt   eric bjerkholt   board dir  stemcells inc   eric bjerkholt email  please login   company name  stemcells inc   company website  wwwstemcellsinccom   company address   porter dr palo alto caunited states   eric bjerkholt profile  board dir  stemcells inc   eric bjerkholt biography  mr bjerkholt is senior vice president and cfo of sunesis pharmaceuticals inc at sunesis he leads the financial operations public and investor relations and treasury activities of the south san francisco small molecule biopharmaceutical company before joining sunesis mr bjerkholt served as senior vice president and cfo of intrabiotics pharmaceuticals inc where he completed multiple financings earlier in his career mr bjerkholt cofounded lifespring nutrition inc a privately held nutraceutical company from 99 to 9 mr bjerkholt was an investment banker at jp morgan  co inc where he founded its western us healthcare investment banking practice leading many equity and financing transactions for biotechnology and other healthcare and life sciences companies mr bjerkholt holds an mba from harvard business school and a cand oecon degree in economics and econometrics from the university of oslo norway   eric bjerkholt colleagues  name title email nobuko uchida vp stem cell biology please login rodney young cfo vp finance administration please login irving weissman board dir please login roger perlmutter board dir please login ann tsukamoto coo please login             home    about us    product information     subscription    list builder     executive list     email lists     contact us    site map    browse directory      � 9 walkerss research  a publisher of business information since 9 all rights reserved  appoints eric h bjerkholt as senior vice president and chief financial officer employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       sunesis pharmaceuticals appoints eric h bjerkholt as senior vice president and chief financial officer tweet 9 9 pm south san francisco calif jan  prnewswire  sunesis pharmaceuticals inc today announced the appointment of eric h bjerkholt to the position of senior vice president and chief financial officer in his new role mr bjerkholt will lead the companys financial operations public and investor relations and treasury activities reporting directly to daniel swisher chief executive officer in addition the company has announced that daniel c adelman md formerly senior vice president clinical development will be assuming increased executive responsibilities for product development in his new role as senior vice president development dr adelman will direct and oversee clinical development regulatory quality control and assurance manufacturing and project management we are very pleased to welcome eric to the sunesis management team this year promises to be an important one for the companys progress and erics expertise in finance administration and investment banking will be a valuable asset as we continue to execute on our plans and manage our resources wisely said mr swisher in addition the expanded responsibilities for dan adelman reflect the companys continued evolution into a researchanddevelopmentbased pharmaceutical company with our first oncology product slated to begin phase i clinical studies later this year sunesis is at an exciting inflection point in its growth towards becoming an integrated pharmaceutical company im excited to join this outstanding management team and look forward to working closely with the board of directors as the company advances its promising pipeline into the clinic commented mr bjerkholt eric h bjerkholt joins sunesis from intrabiotics pharmaceuticals where he has served as senior vice president and chief financial officer while there mr bjerkholt successfully completed multiple financings prior to his tenure at intrabiotics mr bjerkholt was founder cfo president and ceo of lifespring nutrition a privately held nutraceutical company from 99 to 9 mr bjerkholt was vice president at jp morgan  co inc where he led a large number of equity and other transactions in the biotechnology pharmaceutical and other healthcare sectors mr bjerkholt received his mba from harvard business school and a cand oecon degree in mathematical economics from the university of oslo dr adelman joined sunesis in  as senior vice president of clinical development from pharmacyclics inc where he served as vice president of clinical operations and biometrics previously dr adelman served four years at genentech dr adelman began his career at ucsf school of medicine where he continues to serve as adjunct professor of medicine at ucsf he is a fellow of both the american academy of allergy and immunology and the american college of physicians he received his md degree from the university of california davis and his ba degree from uc berkeley sunesis is a researchanddevelopmentbased pharmaceutical company that applies fragmentbased drug discovery to create superior therapeutics for important oncology inflammation and other disease targets sunesis is building a pipeline of innovative therapeutics addressing major diseases through internal development and selective partnering for further information visit httpwwwsunesiscom sunesis pharmaceuticals inc contact eric bjerkholt chief financial officer sunesispharmaceuticals inc 7 media or investors karen lbergman or michelle corral both of bcc partners 79 or79 web site httpwwwsunesiscom read at biospacecom related news sunesis pharmaceuticals announces appointments of daniel swisher to chief executive officer and james young to executive chairmanabgenix abgx announces departure of chief financial officerintrabiotics pharmaceuticals ibpi announces departure of chief financial officerdendreon corporation dndn announces consolidation of san diego operations acquired through recent corvas international inc dndn acquisitionendovasc inc evsc announces new presidentceonanobio forms nanocure corporation to commercialize its drug delivery and imaging technologyaxxima pharmaceuticals ag names yoram karmon president and ceobayer pharma to realign california biotech operations close kyoto center approximately  employees affectedindia glaxo pharmaceutical shuts manufacturing unit to cut costsbiosyntech inc bsyi appoints claude leduc as a chief executive officer please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • sunesis pharmaceuticals inc   • biotechpharma  personnel